Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Simcere Announces Recent Progress of Qiangke’s Registration

May 9, 2011 By Bio-Medicine.Org

NANJING, China, May 9, 2011 /PRNewswire-Asia/ — Simcere
Pharmaceutical Group (“Simcere” or the “Company”) (NYSE:
SCR
), a leading pharmaceutical company specializing in the
development, manufacturing, and marketing of branded and
proprietary pharmaceuticals in China, today announced that Shanghai
Celgen Bio-Pharmaceutical Co., Ltd. (“Shanghai Celgen”) , in which
it holds a 35% equity interest, has received new drug registration
approval for Qiangke, its Recombinant Human TNF Receptor-IgG Fusion
Protein for Injection. Qiangke is primarily used for in-patient
treatment of ankylosing spondylitis and holds strong market
potential. Shanghai Celgen is currently preparing for the upcoming
GMP inspection by the SFDA.

In addition, Simcere plans to purchase the land use rights to
65,300 square meters in Beijing’s Zhongguancun Innovation Park to
establish a regional R&D center and offices. The purchase will
allow Simcere to take advantage of the talent, technology, and
resources available in Beijing.  Simcere has signed a
framework agreement with Beijing Strong Science Park Development
Co., Ltd. for this project.

About Simcere Pharmaceutical GroupSimcere Pharmaceutical
Group (NYSE: SCR, Simcere) is a leading pharmaceutical company
specializing in the development, manufacturing, and marketing of
branded generic and proprietary pharmaceuticals in China. In recent
years, Simcere has been focusing its strategy on the development of
innovative pharmaceuticals and first-to-market generics. The
Company has introduced an innovative anti-cancer medication Endu,
first-to-market generics such as Bicun and Anxin, and a
first-to-market medication Sinofuan. Simcere manufactures and sells
drugs in the oncological, cardiovascular, anti-inflammatory and
anti-infection therapeutical areas. Simcere concentrates its
research and development efforts on the treatment of diseases with
high i

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech